Evolus is staking a position as a hybrid biopharma/beauty company.
Jeuveau is Botox with improved cost structure.
We expect Jeuveau to capture second-place in injectable aesthetics market in 2020.
Strong rationale for a positive outlook for Evolus.
Newport Beach, California-based Evolus (NASDAQ:EOLS) is the newest entrant in the injectable aesthetics market. The business is strategized around a single product, a botulinum toxin marketed as Jeuveau. Their strategy focuses solely on